146 related articles for article (PubMed ID: 1836425)
1. Cholesterol fractions and apolipoproteins during endometriosis treatment by a gonadotrophin releasing hormone (GnRH) agonist implant or by danazol.
Lemay A; Brideau NA; Forest JC; Dodin S; Maheux R
Clin Endocrinol (Oxf); 1991 Oct; 35(4):305-10. PubMed ID: 1836425
[TBL] [Abstract][Full Text] [Related]
2. The effect of danazol and the LHRH agonist analogue goserelin (Zoladex) on the biological activity of luteinizing hormone in women with endometriosis.
Maouris P; Dowsett M; Rose G; Edmonds DK; Rothwell C; Robertson WR
Clin Endocrinol (Oxf); 1990 Oct; 33(4):539-46. PubMed ID: 2146047
[TBL] [Abstract][Full Text] [Related]
3. Bone mass in endometriosis patients treated with GnRH agonist implant or danazol.
Dodin S; Lemay A; Maheux R; Dumont M; Turcot-Lemay L
Obstet Gynecol; 1991 Mar; 77(3):410-5. PubMed ID: 1825135
[TBL] [Abstract][Full Text] [Related]
4. A comparison of the effects of Buserelin versus danazol on plasma lipoproteins during treatment of pelvic endometriosis.
Dlugi AM; Rufo S; D'Amico JF; Seibel MM
Fertil Steril; 1988 May; 49(5):913-6. PubMed ID: 3129319
[TBL] [Abstract][Full Text] [Related]
5. Influence of danazol and goserelin on insulin and glucagon in non-obese women with endometriosis.
Golland IM; Vaughan-Williams CA; Shalet SM; Laing I; Elstein M
Acta Endocrinol (Copenh); 1990 Oct; 123(4):405-10. PubMed ID: 2146853
[TBL] [Abstract][Full Text] [Related]
6. Zoladex versus danazol in the treatment of pelvic endometriosis: effects on plasma lipid risk factors.
Crook D; Gardner R; Worthington M; Nolan J; Stevenson JC; Shaw RW
Horm Res; 1989; 32 Suppl 1():157-60. PubMed ID: 2533147
[TBL] [Abstract][Full Text] [Related]
7. Circulating lipid and lipoprotein concentrations during danazol and high-dose medroxyprogesterone acetate therapy of endometriosis.
Telimaa S; Penttilä I; Puolakka J; Rönnberg L; Kauppila A
Fertil Steril; 1989 Jul; 52(1):31-5. PubMed ID: 2526031
[TBL] [Abstract][Full Text] [Related]
8. Comparison between the effects of nafarelin and danazol on serum lipids and lipoproteins in patients with endometriosis.
Välimäki M; Nilsson CG; Roine R; Ylikorkala O
J Clin Endocrinol Metab; 1989 Dec; 69(6):1097-103. PubMed ID: 2531153
[TBL] [Abstract][Full Text] [Related]
9. An open randomized comparative study of the effect of goserelin depot and danazol in the treatment of endometriosis. Zoladex Endometriosis Study Team.
Shaw RW
Fertil Steril; 1992 Aug; 58(2):265-72. PubMed ID: 1386029
[TBL] [Abstract][Full Text] [Related]
10. Treatment of endometriosis with goserelin depot, a long-acting gonadotropin-releasing hormone agonist analog: endocrine and clinical results.
Venturini PL; Fasce V; Costantini S; Anserini P; Cucuccio S; de Cecco L
Fertil Steril; 1990 Dec; 54(6):1021-7. PubMed ID: 2147154
[TBL] [Abstract][Full Text] [Related]
11. A comparison of the skeletal effects of goserelin and danazol in premenopausal women with endometriosis.
Stevenson JC; Lees B; Gardner R; Shaw RW
Horm Res; 1989; 32 Suppl 1():161-3; discussion 164. PubMed ID: 2533148
[TBL] [Abstract][Full Text] [Related]
12. Goserelin versus danazol in the treatment of endometriosis.
Giorgino FL; Cetera C; de Laurentiis G
Clin Exp Obstet Gynecol; 1991; 18(2):127-31. PubMed ID: 1833094
[TBL] [Abstract][Full Text] [Related]
13. Ovarian suppression induced with Buserelin or danazol in the management of endometriosis: a randomized, comparative study.
Dmowski WP; Radwanska E; Binor Z; Tummon I; Pepping P
Fertil Steril; 1989 Mar; 51(3):395-400. PubMed ID: 2493400
[TBL] [Abstract][Full Text] [Related]
14. Zoladex (goserelin acetate implant) in the treatment of endometriosis: a randomized comparison with danazol. The Zoladex Endometriosis Study Group.
Rock JA; Truglia JA; Caplan RJ
Obstet Gynecol; 1993 Aug; 82(2):198-205. PubMed ID: 8336864
[TBL] [Abstract][Full Text] [Related]
15. Metabolic changes during medical treatment of endometriosis: nafarelin acetate versus danazol.
Burry KA; Patton PE; Illingworth DR
Am J Obstet Gynecol; 1989 Jun; 160(6):1454-9; discussion 1459-61. PubMed ID: 2525337
[TBL] [Abstract][Full Text] [Related]
16. On the origin and significance of serum CA-125 concentrations in 97 patients with endometriosis before, during, and after buserelin acetate, nafarelin, or danazol.
Franssen AM; van der Heijden PF; Thomas CM; Doesburg WH; Willemsen WN; Rolland R
Fertil Steril; 1992 May; 57(5):974-9. PubMed ID: 1533376
[TBL] [Abstract][Full Text] [Related]
17. Changes of plasma lipids and lipoprotein levels during danazol treatment for endometriosis.
Schweppe KW; Assmann G
Horm Metab Res; 1984 Nov; 16(11):593-7. PubMed ID: 6510890
[TBL] [Abstract][Full Text] [Related]
18. GnRH agonists-antagonists--clinical applications.
Shaw RW
Eur J Obstet Gynecol Reprod Biol; 1988 Jun; 28(2):109-16. PubMed ID: 2969835
[TBL] [Abstract][Full Text] [Related]
19. Rationale in use of LHRH analogues in endometriosis.
Shaw RW
Horm Res; 1989; 32 Suppl 1():110-4. PubMed ID: 2533143
[TBL] [Abstract][Full Text] [Related]
20. A randomized, parallel, comparative study of the efficacy and safety of nafarelin versus danazol in the treatment of endometriosis in Taiwan.
Cheng MH; Yu BK; Chang SP; Wang PH
J Chin Med Assoc; 2005 Jul; 68(7):307-14. PubMed ID: 16038370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
